Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MDGL |
---|---|---|
09:32 ET | 1908 | 240.04 |
09:34 ET | 109 | 235.5 |
09:36 ET | 100 | 235.5 |
09:43 ET | 219 | 235.36 |
09:50 ET | 509 | 234.675 |
09:52 ET | 100 | 235.54 |
09:57 ET | 400 | 234.59 |
10:03 ET | 694 | 232.61 |
10:06 ET | 700 | 233.65 |
10:08 ET | 300 | 234.445 |
10:14 ET | 944 | 234.65 |
10:15 ET | 700 | 234.4 |
10:19 ET | 200 | 233.57 |
10:26 ET | 100 | 233.57 |
10:28 ET | 100 | 233.75 |
10:32 ET | 200 | 234.285 |
10:35 ET | 413 | 232.98 |
10:37 ET | 100 | 232.98 |
10:46 ET | 200 | 233.27 |
10:48 ET | 200 | 233.75 |
10:50 ET | 300 | 233.51 |
10:51 ET | 300 | 234.06 |
10:53 ET | 200 | 233.41 |
11:00 ET | 1147 | 233.665 |
11:02 ET | 100 | 234.58 |
11:04 ET | 100 | 234.58 |
11:06 ET | 200 | 234.96 |
11:08 ET | 466 | 235.93 |
11:09 ET | 612 | 236.2 |
11:11 ET | 300 | 237.09 |
11:13 ET | 1352 | 236.59 |
11:20 ET | 300 | 236.62 |
11:22 ET | 100 | 236.75 |
11:24 ET | 600 | 237.145 |
11:26 ET | 228 | 237.83 |
11:27 ET | 400 | 238.15 |
11:29 ET | 100 | 238.77 |
11:31 ET | 384 | 238.96 |
11:33 ET | 100 | 239.05 |
11:36 ET | 300 | 239.15 |
11:38 ET | 200 | 238.4 |
11:40 ET | 1898 | 238.87 |
11:44 ET | 200 | 238.645 |
11:45 ET | 100 | 238.845 |
11:47 ET | 200 | 238.27 |
11:49 ET | 15935 | 239.235 |
11:54 ET | 200 | 239.305 |
11:58 ET | 100 | 239.5 |
12:00 ET | 100 | 238.98 |
12:02 ET | 1100 | 239.22 |
12:03 ET | 406 | 238.88 |
12:05 ET | 900 | 239 |
12:07 ET | 1600 | 239 |
12:09 ET | 200 | 239.48 |
12:12 ET | 412 | 238.845 |
12:14 ET | 1880 | 238.91 |
12:16 ET | 100 | 238.695 |
12:18 ET | 100 | 238.69 |
12:20 ET | 800 | 238.35 |
12:21 ET | 508 | 238.42 |
12:23 ET | 743 | 237.995 |
12:25 ET | 400 | 237.3725 |
12:27 ET | 100 | 237.6275 |
12:30 ET | 309 | 237.97 |
12:32 ET | 406 | 238.145 |
12:36 ET | 300 | 238.2 |
12:38 ET | 110 | 237.9 |
12:39 ET | 408 | 238.075 |
12:43 ET | 105 | 238.105 |
12:45 ET | 915 | 237.57 |
12:48 ET | 108 | 237.735 |
12:50 ET | 390 | 237.6 |
12:52 ET | 100 | 237.115 |
12:54 ET | 205 | 236.55 |
12:56 ET | 100 | 236.9 |
12:57 ET | 530 | 236.795 |
12:59 ET | 100 | 236.78 |
01:01 ET | 406 | 236.69 |
01:03 ET | 100 | 235.78 |
01:06 ET | 200 | 236.68 |
01:10 ET | 312 | 236.515 |
01:14 ET | 1288 | 235.93 |
01:15 ET | 100 | 235.78 |
01:17 ET | 313 | 235.54 |
01:26 ET | 400 | 236.5425 |
01:28 ET | 411 | 236.58 |
01:32 ET | 200 | 236.885 |
01:33 ET | 300 | 236.65 |
01:39 ET | 200 | 236.485 |
01:42 ET | 105 | 236.485 |
01:44 ET | 260 | 236.16 |
01:46 ET | 210 | 235.275 |
01:48 ET | 100 | 234.97 |
01:57 ET | 100 | 235.415 |
02:02 ET | 600 | 235.505 |
02:15 ET | 100 | 235.23 |
02:20 ET | 100 | 235.16 |
02:29 ET | 100 | 235.36 |
02:44 ET | 216 | 235.72 |
02:45 ET | 400 | 236.085 |
02:47 ET | 350 | 235.85 |
02:49 ET | 448 | 235.865 |
02:56 ET | 100 | 235.64 |
02:58 ET | 200 | 235.645 |
03:00 ET | 391 | 235.625 |
03:03 ET | 200 | 236.13 |
03:05 ET | 400 | 235.9 |
03:07 ET | 100 | 235.4 |
03:12 ET | 100 | 234.82 |
03:23 ET | 100 | 234.31 |
03:30 ET | 112 | 234.38 |
03:32 ET | 200 | 235.03 |
03:38 ET | 600 | 234.06 |
03:39 ET | 100 | 234.26 |
03:41 ET | 100 | 234.26 |
03:48 ET | 313 | 234.3975 |
03:50 ET | 216 | 233.89 |
03:52 ET | 500 | 233.22 |
03:54 ET | 600 | 234.2 |
03:56 ET | 600 | 234.45 |
03:57 ET | 1143 | 233.86 |
03:59 ET | 25001 | 233.36 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Madrigal Pharmaceuticals Inc | 5.1B | -9.2x | --- |
BridgeBio Pharma Inc | 4.9B | -10.1x | --- |
Avidity Biosciences Inc | 4.9B | -14.3x | --- |
Immunovant Inc | 4.3B | -15.2x | --- |
Crinetics Pharmaceuticals Inc | 4.3B | -14.1x | --- |
Krystal Biotech Inc | 5.6B | 51.8x | --- |
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.1B |
---|---|
Revenue (TTM) | $14.6M |
Shares Outstanding | 21.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.43 |
EPS | $-25.50 |
Book Value | $20.39 |
P/E Ratio | -9.2x |
Price/Sales (TTM) | 346.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,622.65% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.